161 related articles for article (PubMed ID: 7872714)
21. [Disparity of the bone marrow involvement in a 5-year-old boy with primary non-Hodgkin's malignant lymphoma of the bone].
Tacik J; Skoczeń S; Armata J; Balwierz W
Przegl Lek; 1992; 49(3):102-3. PubMed ID: 1438896
[No Abstract] [Full Text] [Related]
22. Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen.
Kudva GC; Chandy M; Dennison D; Srivastava A; Bhushan V
Indian J Cancer; 1994 Mar; 31(1):1-7. PubMed ID: 8063329
[TBL] [Abstract][Full Text] [Related]
23. Childhood acute lymphoblastic leukaemia: outcomes of 54 consecutive patients treated in Auckland 1985-1991.
Mauger DC; Skeen JE
N Z Med J; 1998 Nov; 111(1078):454-6. PubMed ID: 9891565
[TBL] [Abstract][Full Text] [Related]
24. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
[TBL] [Abstract][Full Text] [Related]
25. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
[TBL] [Abstract][Full Text] [Related]
26. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
27. Diversity of the apoptotic response to chemotherapy in childhood leukemia.
Liu T; Raetz E; Moos PJ; Perkins SL; Bruggers CS; Smith F; Carroll WL
Leukemia; 2002 Feb; 16(2):223-32. PubMed ID: 11840289
[TBL] [Abstract][Full Text] [Related]
28. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
29. Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies.
Tsai T; Davalath S; Rankin C; Radich JP; Head D; Appelbaum FR; Boldt DH
Leukemia; 1996 Dec; 10(12):1901-10. PubMed ID: 8946929
[TBL] [Abstract][Full Text] [Related]
30. [Anemia and recurrences in acute lymphoblastic leukemia in children after the treatment and the frequency of the erythroblasts with micronuclei].
Rytwiński K; Sońta-Jakimczyk D; Konopacka M; Ciechanowska U
Acta Haematol Pol; 1992; 23(2):95-9. PubMed ID: 1488866
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
34. Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication.
Schrøder H; Kjeldahl M; Boesen AM; Nielsen OJ; Schmidt K; Johnsen HE; Gregersen H; Heyman M; Gustafsson G
Dan Med Bull; 2006 Feb; 53(1):76-9. PubMed ID: 16761337
[TBL] [Abstract][Full Text] [Related]
35. The chemosensitivity to therapy of childhood early B acute lymphoblastic leukemia could be determined by the combined expression of CD34, SPI-B and BCR genes.
Talby L; Chambost H; Roubaud MC; N'Guyen C; Milili M; Loriod B; Fossat C; Picard C; Gabert J; Chiappetta P; Michel G; Schiff C
Leuk Res; 2006 Jun; 30(6):665-76. PubMed ID: 16297978
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia.
Visser JH; Wessels G; Hesseling PB; Louw I; Oberholster E; Mansvelt EP
Pediatr Hematol Oncol; 2001; 18(3):187-91. PubMed ID: 11293286
[TBL] [Abstract][Full Text] [Related]
37. Plasma protein fractions and alpha 1-acidglycoprotein as tumor markers in acute lymphoblastic leukemia.
Abdalla A; Badrawy F; Khalifa A; Hamza R
Chemioterapia; 1987 Jun; 6(2 Suppl):743-4. PubMed ID: 3509537
[No Abstract] [Full Text] [Related]
38. Mitochondrial D-loop polymorphisms and mitochondrial DNA content in childhood acute lymphoblastic leukemia.
Kwok CS; Quah TC; Ariffin H; Tay SK; Yeoh AE
J Pediatr Hematol Oncol; 2011 Aug; 33(6):e239-44. PubMed ID: 21646920
[TBL] [Abstract][Full Text] [Related]
39. Relapses after termination of therapy of acute lymphoblastic leukemia in children.
Ochocka M; Matysiak M; Kulus M; Armata J; Balwierz W; Bogusławska-Jaworska J; Chybicka A; Jackowska T; Jakowicka M; Michalewska D
Acta Paediatr Jpn; 1993 Oct; 35(5):377-81. PubMed ID: 8256619
[TBL] [Abstract][Full Text] [Related]
40. [L-asparaginase therapy against hybrid leukemia: a case report].
Mitani K; Kobayashi Y; Kawamura Y; Usuki K; Yuo A; Ishikawa F; Kitamura T; Ozawa K; Kitamura K; Urabe A
Rinsho Ketsueki; 1988 Sep; 29(9):1442-6. PubMed ID: 3216516
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
